Abstract
Objective: To estimate the cost effectiveness of different classes of antidepressants in the UK National Health Service.
Design, patients and interventions: The use of the serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) venlafaxine was compared with that of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) in patients with major depressive disorder (MDD). A meta-analysis determined the clinical success rate, and a decision tree was constructed by interviewing general practitioners and psychiatrists. Adding pharmacological and nonpharmacological treatment costs, meta-analytic rates were applied to the decision tree to calculate the expected cost and outcome for each drug. Cost effectiveness was determined using a composite measure of outcome [symptom-free days (SFD)].
Main outcome measures and results: The meta-analysis included data from 44 studies on 4033 patients. The highest overall efficacy rate for outpatients with MDD was with venlafaxine use (73.7%), compared with 61.4% for SSRIs and 59.3% for TCAs. Treatment with venlafaxine yielded the lowest outpatient cost for a SFD (£10.53), compared with £13.23 for SSRIs and £15.52 for TCAs (1998 values).
Conclusions: Using this economic model, venlafaxine appears to be a cost-effective treatment for outpatients with MDD in the UK.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jenkins R, Lewis G, Bebbington P, et al. The National Psychiatric Morbidity surveys of Great Britain: initial findings from the household survey. Psychol Med 1997; 27 (4): 775–89
Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press, 1996
Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7 (3–4): 191–5
Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997: 12 (1): 19–29
OECD (Organization for Economic Co-operation and Development) Health data 1997. Available from: http://www.oecdwash.org/PRESS/PRESRELS/1999/99013tb1.pdf
Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164 (5): 665–73
Nuijten MJ, Hardens M, Souetre E. A Markov process analysis comparing the cost-effectiveness of maintenance therapy with citalopramversus standard therapy in major depression. Pharmacoeconomics 1995; 8 (2): 159–68
Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12 (2 Pt 2): 286–96
Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999; 21 (2): 296–308
Einarson TR, Arikian SR, Doyle JJ. Rank-order stability analysis (ROSA): testing pharmacoeconomic data. Med Decis Making 1995: 15 (4): 367–72
Acknowledgements
This work was sponsored by an unrestricted grant from Wyeth Laboratories.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freeman, H., Arikian, S. & Lenox-Smith, A. Pharmacoeconomic Analysis of Antidepressants for Major Depressive Disorder in the United Kingdom. Pharmacoeconomics 18, 143–148 (2000). https://doi.org/10.2165/00019053-200018020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200018020-00004